FDA adverse event reporting of ACEI and ARB associated angioedema

被引：3
|
作者：
Thaker, D
Frech, F
Gil, M
机构：
[1] Univ Texas, Austin, TX 78712 USA
[2] Novartis Pharmaceut Corp, Hlth Econ & Outcomes Res, E Hanover, NJ USA
[3] Novartis Pharmaceut Corp, Barcelona, Spain
来源：
AMERICAN JOURNAL OF HYPERTENSION | 2005年 / 18卷 / 05期
关键词：
AERS database; angioedema;
D O I：
10.1016/j.amjhyper.2005.03.325
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：116A / 116A
页数：1
相关论文
共 50 条
  • [1] IN VIDEO, FDA URGES ADVERSE EVENT REPORTING
    Cima, Greg
    JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2021, 259 (03): : 223 - 223
  • [2] Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
    Fan, Maoxia
    Niu, Kaibin
    Wu, Xiaoqi
    Shi, Hongshuo
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [3] ACEI associated angioedema
    Smith, William B.
    O'Hehir, Robyn E.
    AUSTRALIAN FAMILY PHYSICIAN, 2012, 41 (03) : 89 - 89
  • [4] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [5] Fosfomycin-associated adverse events: A disproportionality analysis of the FDA Adverse Event Reporting System
    Yang, Luxuan
    Zhang, Wenyong
    Shen, Xiujuan
    Liu, Meiqin
    Wu, Meiying
    Xiao, Dan
    DRUG DISCOVERIES AND THERAPEUTICS, 2025,
  • [6] Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
    Shu, Yamin
    Ding, Yiling
    Liu, Lulu
    Zhang, Qilin
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2705 - 2716
  • [7] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [8] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [9] Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System
    Huang, Shulan
    Dong, Hanlin
    Luo, Dongqiang
    Jiang, Jiazhen
    Liu, Manting
    Wu, Jiayu
    Dou, Xiangyun
    Zhou, Siyuan
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [10] Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system
    Ohyama, Katsuhiro
    Katagiri, Seiichiro
    Takahashi, Satoshi
    Ayuhara, Hideaki
    Takeuchi, Hironori
    Akahane, Daigo
    Gotoh, Akihiko
    Hori, Yusuke
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2025, 63 (01) : 30 - 37
12345